SCHEMBL5535600

SCHEMBL5535600

Cc1ccccc1O[CH]c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN4A P35499 2/20 0.42
TSHR P16473 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
ALDH1A1 P00352 2/20 0.39
AOC2 O75106 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
NFE2L2 Q16236 2/20 0.38
TRPA1 O75762 1/20 0.38
ACHE P22303 1/20 0.38
MAPT P10636 2/20 0.36
GLA P06280 1/20 0.36
ALOX15 P16050 1/20 0.36
TTR P02766 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535900 0.86 MAPT (0.42) SCN4ANPC1RAB9AMEN1KMT2A
SCHEMBL5545764 0.80 TSHR (0.40) TSHRNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL5542020 0.80 NFE2L2 (0.41) TSHRNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL30266504 0.79 NFE2L2 (0.44) SCN4ATSHRNPC1RAB9ASMN1; SMN2
SCHEMBL10506262 0.79 NFE2L2 (0.44) SCN4ATSHRNPC1RAB9ASMN1; SMN2
SCHEMBL5544907 0.78 SCN4A (0.38) SCN4ATSHRNPC1RAB9ASMN1; SMN2
SCHEMBL5547846 0.78 CA1 (0.56) TSHRSMN1; SMN2KMT2ACYP1A2ALDH1A1
SCHEMBL534786 0.75 TSHR (0.45) SCN4ATSHRNPC1RAB9ASMN1; SMN2
SCHEMBL6001493 0.74 NFE2L2 (0.42) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL5542469 0.74 ALDH1A1 (0.42) MEN1KMT2AKDM4ECYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SCN4A 2592/4885TSHR 319/4885NPC1 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.